diabetestalk.net

Can Taking Metformin Cause Bladder Cancer?

Bladder Cancer Recurrence Risk Lower In Metformin Users

Bladder Cancer Recurrence Risk Lower In Metformin Users

Bladder Cancer Recurrence Risk Lower in Metformin Users Bladder Cancer Recurrence Risk Lower in Metformin Users The protective effect of the diabetes drug metformin among patients who undergo surgery for non-muscle invasive bladder cancer is dose dependent, according to a study. The following article is part ofconferencecoverage from the 2017 American Urological Association meeting in Boston.Renal and Urology News'staff will be reporting live on medical studies conducted by urologists and other specialists who are tops in their field in kidney stones, prostate cancer, kidney cancer, bladder cancer, enlarged prostate, and more. Check back for the latest news from AUA 2017. BOSTONMetformin use at the time of transurethral resection (TUR) of non-muscle invasive bladder cancer (NMIBC) is associated with improved recurrence-free survival, according to study findings presented at the American Urological Association 2017 annual meeting. Results also showed that metformin doses of 2000 mg or more are independently associated with decreased recurrence risk. In a study of 503 patients who underwent TUR for NMIBC, Timothy Rushmer, a fourth-year medical student at the University of Wisconsin in Madison, and colleagues found that, on multivariate analysis, diabetic patients on metformin at the time of TUR had a significant 49% and 40% decreased risk of disease recurrence compared with diabetic patients not on metformin and non-diabetic patients not on metformin, respectively. The 5-year recurrence-free survival rate was 42.3% for diabetic patients on metformin compared with 9.7% among diabetics not on metformin, and 35.1% for non-diabetics not on metformin. The study population had a median age of 70.6 years. The median time to recurrence was 15 months. In a separate multivariate a Continue reading >>

Diabetes Drug Linked To Increased Bladder Cancer Risk

Diabetes Drug Linked To Increased Bladder Cancer Risk

Diabetes drug linked to increased bladder cancer risk Diabetes drug linked to increased bladder cancer risk "The anti-diabetic drug pioglitazone raises the risk of bladder cancer by 63 per cent," The Daily Telegraph reports. While the actual increased risk in real-world terms is small, the results may help to inform prescription decisions for both doctors and patients. Pioglitazone is a drug that helps people with type 2 diabetes by making their cells more sensitive to insulin. Some previous studies have linked pioglitazone with a raised chance of bladder cancer , although the results ofprevious research have been inconclusive. The new study looked at what happened to 145,806 people who took pioglitazone compared to other oral diabetes drugs (not insulin) over a 14-year period (2000 to 2014). Researchers found that people who had taken pioglitazone, as opposed to other diabetes drugs, were 63% more likely to have been diagnosed with bladder cancer, and that the risk increased the longer they had taken it. It is important to note that the overall risk of bladder cancer was low. There were 121 cases of bladder cancer for every 10,000 people taking pioglitazone for 10 years, compared to 89 cases for people taking other diabetes drugs. For people who respond well to this drug, the benefits in terms of diabetes control are thought to outweigh the risks. Anyone taking pioglitazone should continue the drug as prescribed, but discuss any concerns they have with their doctor, and immediately report any symptoms such as blood in urine, frequent urination, or pain when passing urine. The study was carried out by researchers from the Jewish General Hospital and McGill University, both in Montreal, Canada, and was funded by the Canadian Institutes of Health Research. The study was Continue reading >>

Metformin: Can A Diabetes Drug Help Prevent Cancer?

Metformin: Can A Diabetes Drug Help Prevent Cancer?

In 1957, the first results from a clinical trial of the diabetes drug metformin in patients were published. Yet, it would take nearly 40 years for the drug to be approved in the United States as a treatment for type 2 diabetes. Now researchers want to know whether this decades-old drug may have additional uses in another disease—cancer. Based on findings from a number of large epidemiologic studies and extensive laboratory research, metformin is being tested in clinical trials not only as a treatment for cancer, but as a way to prevent it in people at increased risk, including cancer survivors who have a higher risk of a second primary cancer. Numerous early-stage clinical trials are currently under way to investigate metformin’s potential to prevent an array of cancers, including colorectal, prostate, endometrial, and breast cancer. Several of these trials are being funded by NCI’s Consortia for Early Phase Prevention Trials. And NCI is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to study participants from the landmark clinical trial, the Diabetes Prevention Program (DPP), to investigate metformin’s impact on cancer incidence. Some of the early-phase prevention trials of metformin are enrolling participants who are at increased risk for cancer and who are obese, have elevated glucose or insulin levels, or have other conditions that put them at risk for diabetes. “With the obesity epidemic, these studies are applicable to a substantial portion of the U.S. population and, increasingly, of the world population,” said Brandy Heckman-Stoddard, PhD, MPH, of NCI’s Division of Cancer Prevention. Expanding the Data Pool Much of the human data on metformin and cancer has come from epidemiologic studies of people w Continue reading >>

Bladder Cancer Risk Factors

Bladder Cancer Risk Factors

Bladder cancer cases linked to exposure to tobacco smoke, UK Bladder cancer cases linked to occupational exposures, UK 42% (44% in males and 37% in females) of bladder cancer cases each year in the UK are linked to major lifestyle and other risk factors[ 1 ] Bladder cancer risk is associated with a number of risk factors[ 2,3 ]. Arsenic and inorganic arsenic compounds[a] Hairdressers and barbers, occupational exposure International Agency for Research on Cancer (IARC) andWorld Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) classifications. a WCRF/AICR classifies evidence on arsenic in drinking water as probable Use our interactive tool to explore risk factors for bladdercancer World Cancer Research Fund / American Institute for Cancer Research. Continuous Update Project Findings & Reports . Accessed October 2016. Tobacco smoking is classified by the International Agency for Research on Cancer (IARC) as a cause of bladder cancer.[ 1 ] An estimated 37% of bladder cancers in the UK are linked to tobacco smoking.[ 2 ] Bladder cancer risk is around 2-4 times higher in current smokers compared with never-smokers, meta-analyseshave shown.[ 3-5 ] Bladder cancer risk increases with amount and duration of smoking, a meta-analysis and pooled analyses of case-control studies have shown.[ 6-8 ] Bladder cancer risk is 73-80% lower in ex-smokers who quit 25 years previously, compared with ongoing smokers, pooled analyses have shown; however, ex-smokers risk remains higher than never-smokers risk.[ 7,8 ] Higher bladder cancer risk in smokers may partly reflect mutual confounding by occupational exposures.[ 9 ] View our health information on smoking and cancer 't Mannetje A, Kogevinas M, Chang-Claude J, et al. Smoking as a confounder in case-control studies of Continue reading >>

Metformin And Gefitinib Cooperate To Inhibit Bladder Cancer Growth Via Both Ampk And Egfr Pathways Joining At Akt And Erk

Metformin And Gefitinib Cooperate To Inhibit Bladder Cancer Growth Via Both Ampk And Egfr Pathways Joining At Akt And Erk

Article | Open Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk Scientific Reports volume 6, Articlenumber:28611 (2016) EGFR is a potential therapeutic target for treating bladder cancer, but has not been approved for clinical use yet. Metformin is a widely used antidiabetic drug and has demonstrated interesting anticancer effects on various cancer models, alone or in combination with chemotherapeutic drugs. The efficacy of gefitinib, a well-known EGFR tyrosine kinase inhibitor, combined with metformin was assessed on bladder cancer and underlying mechanisms were explored. This drug combination induced a strong anti-proliferative and anti-colony forming effect and apoptosis in bladder cancer cell lines. Gefitinib suppressed EGFR signaling and inhibited phosphorylation of ERK and Akt. Metformin amplified this inhibitory effect and enhanced gefitinib-induced activation of AMPK signaling pathway. In vivo intravesical treatment of metformin and gefitinib on syngeneic orthotopic mice confirmed the significant inhibitory effect on bladder tumor growth. These two drugs may be an excellent combination for the treatment of bladder cancer through intravesical instillation. Bladder cancer is one of the most common cancers of the urinary tract in the world, accounting for about 74,000 new cases and 16,000 deaths in the United State in 2015 1 . Although radical cystectomy with chemotherapy has been applied for treating bladder cancer patients as the standard clinical administration and exerted efficient benefits, recurrence and metastasis take place frequently 2 . To prevent recurrence and progression, intravesical chemotherapy or immunosuppressive agents have been widely used after radical cystectomy 3 , 4 . Continue reading >>

Pioglitazone Bladder Cancer Link Seen Again

Pioglitazone Bladder Cancer Link Seen Again

Pioglitazone Bladder Cancer Link Seen Again But absolute risk remains low overall, finds large British study by Parker Brown Parker Brown, Staff Writer, MedPage Today This article is a collaboration between MedPage Today and: Note that this observational study of British patients with diabetes found that the use of pioglitazone, compared with other antidiabetic agents, was associated with an increased risk of bladder cancer. Be aware that the absolute risk of bladder cancer in the population was quite low. Pioglitazone (Actos) was associated with a higher risk of bladder cancer than other diabetes drugs in a large population-based cohort study. Researchers looked at about 146,000 patients in the U.K. who had recently started taking an anti-diabetic drug; those on pioglitazone faced an increased risk of bladder cancer of 121.0 versus 88.9 per 100,000 person-years among those on other diabetes drugs (hazard ratio 1.63, 95% CI 1.22-2.19). Fifty-four patients receiving pioglitazone were diagnosed with cancer after a mean follow-up of 4.7 years. But those on rosiglitazone (Avandia) didn't see an increased risk of bladder cancer (HR 1.10, 95% CI 0.83-1.47), according to lead author Marco Tuccori, PhD , at the Jewish General Hospital in Montreal, Canada, suggesting that the increased risk was not a class effect. Tuccori and colleagues published their findings on Wednesday in The BMJ . In 2015, Actos manufacturer Takeda agreed to pay $2.4 billion to settle lawsuits alleging that it hid bladder cancer risks associated with the drug from patients. The new study is the latest in a long-running seesaw drama, with one study identifying an increased bladder cancer risk with the drug, only to be followed by another showing no link. The latest results support findings from a 2005 tria Continue reading >>

Pioglitazone Use And Risk Of Bladder Cancer: Population Based Cohort Study

Pioglitazone Use And Risk Of Bladder Cancer: Population Based Cohort Study

Pioglitazone use and risk of bladder cancer: population based cohort study Pioglitazone use and risk of bladder cancer: population based cohort study BMJ 2016; 352 doi: (Published 30 March 2016) Cite this as: BMJ 2016;352:i1541 Kristian B Filion, assistant professor of medicine 1 2 3 , Robert W Platt, professor of biostatistics 1 2 5 6 , Laurent Azoulay, associate professor of oncology 1 7 1Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada 2Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal 3Division of Clinical Epidemiology, McGill University 4Division of Endocrinology, Jewish General Hospital, Montreal 5Department of Pediatrics, McGill University, Montreal 6Research Institute of the McGill University Health Centre, Montreal 7Department of Oncology, McGill University Correspondence to: L Azoulay laurent.azoulay{at}mcgill.ca ObjectiveTo determine whether pioglitazone compared with other antidiabetic drugs is associated with an increased risk of bladder cancer in people with type 2 diabetes. SettingGeneral practices contributing data to the United Kingdom Clinical Practice Research Datalink. ParticipantsA cohort of 145 806 patients newly treated with antidiabetic drugs between 1 January 2000 and 31 July 2013, with follow-up until 31 July 2014. Main outcome measuresThe use of pioglitazone was treated as a time varying variable, with use lagged by one year for latency purposes. Cox proportional hazards models were used to estimate adjusted hazard ratios with 95% confidence intervals of incident bladder cancer associated with pioglitazone overall and by both cumulative duration of use and cumulative dose. Similar analyses were conducted for rosiglitazone, a thiazolidinedion Continue reading >>

Metformin Fails To Reduce Bladder Cancer Risk, Safer Than Actos: Study

Metformin Fails To Reduce Bladder Cancer Risk, Safer Than Actos: Study

Metformin Fails To Reduce Bladder Cancer Risk, Safer Than Actos: Study Researchers were disappointed to find that the drug metformin did not reduce the risk of bladder cancer among individuals with type 2 diabetes, but they did find that it does not increase the bladder cancer risk, like several studies have suggested side effects of Actos does. In a study published this month in the medical journal Diabetes Care , researchers from the University of Pennsylvanias Abramson Cancer Center found that patients taking metformin or drugs from a class known as sulfonylureas, like Dymelor and Orinase, did not see a reduction in the rate of bladder cancer. Bladder cancer is a potential risk that may be associated with diabetes, and researchers hoped that the diabetes drug metformin may have a prophylactic effect. However, after looking at data involving 87,000 patients with diabetes in The Health Improvement Network, researchers indicate that they found no statistical difference in the bladder cancer rates among those who took the drugs and those who did not. Researchers did recommend scientists take a look at metformin in comparison to other cancer rates as well, as bladder cancer is only one type of cancer some believed metformin may help prevent. Use of metformin is not associated with a decreased incidence of bladder cancer, the researchers concluded. Similar methods should be used to study other cancers that have previously been identified as potentially preventable with metformin. The study comes amid continuing concerns about the link between bladder cancer and Actos , a competing diabetes drug. While all diabetes patients may face a slight increase in the risk of bladder cancer, several studies have suggested that long-term Actus users face a substantially increased risk Continue reading >>

Actos

Actos

Actos (pioglitazone) is an oral Type 2 diabetes drug that lowers blood sugar by decreasing insulin resistance and reducing the amount of glucose made in the liver. This allows the body to better dispose of excess blood sugar. Typically, the dose starts at 15 or 30 mg and is taken once a day, but some people may require a stronger dose. Doctors can increase the strength of the medicine by 15 mg increments to a maximum of 45 mg daily. However, numerous studies and a review by the U.S. Food and Drug Administration (FDA) link higher dosages and prolonged use to an increased risk of bladder cancer and other serious conditions. Actos is not intended to treat Type 1 diabetes or diabetic ketoacidosis. The drug can be used alone or with other Type 2 diabetes medicines such as metformin. There are two additional types of Actos that combine pioglitazone and metformin: Actoplus Met and Actoplus Met XR (extended release). What Does Actos Treat? Actos is approved to treat Type 2 diabetes in adults by improving glycemic (defined as causing glucose – sugar – in the blood) control. The drug comes in a tablet form to be taken by mouth daily and should be used in combination with diet and exercise. People with Type 2 diabetes do not make or use insulin well. Insulin is a hormone produced by the pancreas that regulates the amount of glucose in the blood. It moves blood sugar into cells where it is stored for later use as energy. Type 2 diabetes results in higher than normal levels of glucose because glucose does not enter cells. The body is then unable to use the glucose for energy. Type 2 diabetes is a lifelong (chronic) disease that can develop at any age, including during childhood. However, it mostly occurs in middle-aged and older people. The condition often develops slowly over t Continue reading >>

Pioglitazone And Metformin (oral Route)

Pioglitazone And Metformin (oral Route)

Precautions Drug information provided by: Micromedex It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects. Check with your doctor right away if you start having chest pain; shortness of breath; excessive swelling of the hands, wrist, ankles, or feet; or if you are rapidly gaining weight. These may be symptoms of a serious heart problem. Let your doctor or dentist know you are taking this medicine. Your doctor may advise you to stop taking this medicine before you have major surgery or diagnostic tests, especially tests that use a contrast dye. Under certain conditions, too much metformin can cause a serious condition called lactic acidosis. The symptoms of lactic acidosis are severe and appear quickly. Lactic acidosis usually occurs when other serious health problems are present, such as a heart attack or kidney failure. The symptoms of lactic acidosis include: abdominal or stomach discomfort; decreased appetite; diarrhea; fast or shallow breathing; a general feeling of discomfort; muscle pain or cramping; and unusual sleepiness, tiredness, or weakness. If you have more than one of these symptoms together, you should get immediate emergency medical help. Tell your doctor right away if you have any of these symptoms: loss of appetite, nausea, vomiting, stomach pain, unusual tiredness or weakness, weight loss, or yellow eyes or skin. These may be symptoms of a serious liver problem. Check with your doctor right away if blurred vision, decreased vision, or any other change in vision occurs while you are taking this medicine. Your doctor may want you to have your eyes checked by an ophthalmologist (eye doctor). Certain women may be at Continue reading >>

Metformin May Have A Protective Effect In Bladder Cancer Patients

Metformin May Have A Protective Effect In Bladder Cancer Patients

Metformin May Have a Protective Effect in Bladder Cancer Patients Metformin May Have a Protective Effect in Bladder Cancer Patients Diabetics taking the drug had a significant 68% decreased risk of grade progression compared with diabetics not on the drug. Metformin use may decrease the risk of grade progression in patients with non-muscle invasive bladder cancer (NMIBC), according to study findings presented at the Canadian Urological Association 2016 annual meeting in Vancouver. Samer L. Traboulsi, MD, and colleagues at McGill University Health Centre in Montreal conducted a retrospective analysis of 1,356 NMIBC patients with a median age of 69.5 years. The cohort consisted of 1,197 patients (88.3%) without diabetes, 93 patients (6.9%) with diabetes on metformin, and 66 patients (4.9%) with diabetes and not on metformin who served as a reference group. In multivariate analysis, metformin use was not associated with disease recurrence and stage and disease progression, but it was associated with a significant 68% decreased risk of grade progression compared with the reference group. In addition, patients without diabetes had a significant 42% lower risk for disease progression compared with the reference group. Metformin is hypothesized to have antineoplastic activity due to its inhibitor activity on mammalian target of rapamycin, the researchers explained in a poster presentation. Investigations in clinical trials are needed to show whether metformin mitigates the deleterious effect of diabetes on stage progression, Dr. Traboulsi's group concluded. Previously, in a paper published in Urologic Oncology (2015;33:386.e7-386.e13), Canadian researchers reported on a study of 421 patients undergoing radical cystectomy for bladder cancer showing that metformin users had a 6 Continue reading >>

Does Pioglitazone Increase The Risk Of Bladder Cancer?

Does Pioglitazone Increase The Risk Of Bladder Cancer?

Does pioglitazone increase the risk of bladder cancer? Pioglitazone is a medicine in the glitazone family which may slightly increase the risk of bladder cancer.This is still under investigation, but below is some information about the current concerns. Since 2000, several studies have been running to try to identify a possible link between pioglitazone and bladder cancer. Initial studies were inconclusive. However, there were more spontaneous reports than expected of people on pioglitazone being found to have bladder cancer. A European-wide review in July 2011 found a small increase in the risk of bladder cancer in people taking pioglitazone, especially after long-term use. Assessing people for risk of bladder cancer before starting treatment could help to reduce this small risk and allow people for whom pioglitazone is the best option in terms of their diabetes, to benefit from the drug. Symptoms such as needing to pass urine frequently or pain on passing urine without a clear cause (such as a urine infection) Occupational exposure to certain dyes (used in textiles and industry, probably not standard hair dyes) Certain infections such as schistosomiasis (uncommon in the UK). The advantages of pioglitazone in terms of glucose control may outweigh the risks in some cases. For those taking pioglitaone, tell your doctor if you notice any blood in your urine or any other symptom relating to your urine or bladder. Doctors should review risk of bladder cancer before starting treatment and review the treatment every three to six months. Other factors may also be important as pioglitazone may increase the risk of fractures and of developing pneumonia. More information on risk factors from Cancer Research UK. Recommendations from the European Medical Agency. Continue reading >>

No Bladder-cancer Protection With Metformin, New Study Finds

No Bladder-cancer Protection With Metformin, New Study Finds

No Bladder-Cancer Protection With Metformin, New Study Finds The most commonly used medication for type 2 diabetes, metformin, may not offer protection from bladder cancer, the findings of a new cohort study suggest. Previous observational studies have linked metformin use with a reduction in cancer of the breast, colon , liver, lung , and pancreas , and 2 recent meta-analyses have shown an overall 30% reduction in all cancers with metformin compared with other diabetes medications. However, few data are available for bladder cancer, say Ronac Mamtani, MD, attending physician, hematology-oncology, Philadelphia Veterans Affairs Medical Center, Pennsylvania, and colleagues in their article, published online February 4 in Diabetes Care. Bladder cancer in particular is important both because people with type 2 diabetes have about a 40% increased risk of developing it and because another diabetes drug, the thiazolidinedione pioglitazone, has been linked with a possible increased risk . Use of metformin was not associated with a significantly decreased risk for bladder cancer at a median follow-up of about 2 years in the new study (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.60 1.09), say the authors. "In the UK's Health Improvement Network (THIN) patient population, we found no evidence for a decreased risk of bladder cancer in type 2 diabetes patients using metformin," they write. But Peter T. Donnan, PhD, professor of epidemiology and biostatistics, population health sciences, University of Dundee, and codirector of Tayside Clinical Trials Unit, Scotland, disagrees. "The findings indicate a 19% reduction in hazard for bladder cancer associated with use of metformin. The value of the HR is not inconsistent with previous findings in individual studies as well a Continue reading >>

Will You Have Bladder Cancer With Metformin - From Fda Reports - Ehealthme

Will You Have Bladder Cancer With Metformin - From Fda Reports - Ehealthme

A study for a 72 year old woman who takes Reclast NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered. WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health. DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. You may report adverse side effects to the FDA at or 1-800-FDA-1088 (1-800-332-1088). If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date. Continue reading >>

Can Metformin Cause Bladder Cancer?

Can Metformin Cause Bladder Cancer?

Clorazepam Rigevidon Weight Gain Belviq vs Phentermine Brintellix and Alcohol Nexplanon Weight Loss Treato does not review third-party posts for accuracy of any kind, including for medical diagnosis or treatments, or events in general. Treato does not provide medical advice, diagnosis or treatment. Usage of the website does not substitute professional medical advice. The side effects featured here are based on those most frequently appearing in user posts on the Internet. The manufacturer's product labeling should always be consulted for a list of side effects most frequently appearing in patients during clinical studies. Talk to your doctor about which medications may be most appropriate for you. The information reflected here is dependent upon the correct functioning of our algorithm. From time-to-time, our system might experience bugs or glitches that affect the accuracy or correct application of mathematical algorithms. We will do our best to update the site if we are made aware of any malfunctioning or misapplication of these algorithms. We cannot guarantee results and occasional interruptions in updating may occur. Please continue to check the site for updated information. Continue reading >>

More in diabetes